In this piece, we will take a look at the top five best stocks to buy under $20 according to billionaire Andreas Halvorsen’s Viking Global. If you want to learn more about the hedge fund, its founder, and other stocks, then head on to 10 Best Stocks Under $20 According to Billionaire Andreas Halvorsen’s Viking Global.
5. Farfetch Limited (NYSE:FTCH)
Viking Global’s Stake Value: $198.7 million
Percentage of Viking Global’s 13F Portfolio: 0.57%
Number of Hedge Fund Holders: 47
Share Price on April 26, 2022: $11.58
Farfetch Limited (NYSE:FTCH) is an online marketplace provider for luxury fashion goods. The company is based out of London, United Kingdom and it provides its services in the U.S., the U.K., and globally.
Mr. Halvorsen’s hedge fund owned a $198 million stake in Farfetch Limited (NYSE:FTCH) as Q4 2021 came to an end. This was in the form of 5.9 million shares. During the same time period, 47 of the 924 hedge funds polled by Insider Monkey had also invested in the company.
Farfetch Limited (NYSE:FTCH)’s fiscal fourth quarter results saw the company post $666 million in revenue and -$0.03 in non-GAAP EPS, which missed analyst revenue estimates but beat them for EPS. BTIG lowered its price target to $26 from $34 in April 2022 outlining that the company’s performance had improved in March.
Stephen Mandel’s Lone Pine Capital is Farfetch Limited (NYSE:FTCH)’s largest investor. It owns 24.4 million shares that are worth $817 million.
4. Inhibrx, Inc. (NASDAQ:INBX)
Viking Global’s Stake Value: $231.7 million
Percentage of Viking Global’s 13F Portfolio: 0.67%
Number of Hedge Fund Holders: 14
Share Price on April 26, 2022: $15.40
Inhibrx, Inc. (NASDAQ:INBX) is a biotechnology company based in La Jolla, California, United States. It develops treatments for several kinds of cancers, solid tumors, and deficiencies.
By the end of its fiscal Q4, Inhibrx, Inc. (NASDAQ:INBX) reported $2.86 million in revenue and -$0.55 in GAAP EPS, for a strong set of results that saw the company beat analyst estimates for both. SMBC Nikko set a $40 price target for the company in March 2022, stating that it is developing promising treatments.
Viking Global owned 5.3 million Inhibrx, Inc. (NASDAQ:INBX) shares by the end of last year’s fourth quarter. This resulted in it having a $231 million stake that represented 0.67% of its investment portfolio. Insider Monkey surveyed 924 hedge funds for the same time period to discover that 14 had also bought the company’s shares.
Inhibrx, Inc. (NASDAQ:INBX)’s largest investor after Viking Global is Joseph Edelman’s Perceptive Advisors which owns 1.3 million shares that are worth $58 million.
3. FIGS, Inc. (NYSE:FIGS)
Viking Global’s Stake Value: $406 million
Percentage of Viking Global’s 13F Portfolio: 1.17%
Number of Hedge Fund Holders: 16
Share Price on April 26, 2022: $16.03
FIGS, Inc. (NYSE:FIGS) is an American healthcare apparel provider. It offers garments such as scrubs, lifestyle garments, socks, masks, lab coats, and outerwear.
Mr. Halvorsen’s hedge fund held a $406 million stake in FIGS, Inc. (NYSE:FIGS) for its Q4 2021 investment portfolio via owning 14.7 million shares. Insider Monkey’s 924 hedge fund portfolio analysis for the same time period revealed 16 as having invested in the company.
FIGS, Inc. (NYSE:FIGS) raked in $128 million in revenue and $0.09 in non-GAAP EPS for its fiscal fourth quarter, beating analyst estimates for both. Truist set a $32 price target for the company in April 2022, sharing that it believes that the company can post as much as $1 billion in sales in 2025.
George Soros’s Soros Fund Management is FIGS, Inc. (NYSE:FIGS)’s largest investor after Viking Global through a $49.6 million stake that comes via 1.8 million shares.
2. BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Viking Global’s Stake Value: $444 million
Percentage of Viking Global’s 13F Portfolio: 1.28%
Number of Hedge Fund Holders: 25
Share Price on April 26, 2022: $9.61
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is an American biopharmaceutical company headquartered in Palo Alto, California. It develops products that are used to treat a host of genetic diseases such as amyloidosis-cardiomyopathy, congenital adrenal hyperplasia, and Autosomal Dominant Hypocalcemia Type 1.
For its fiscal fourth quarter, BridgeBio Pharma, Inc. (NASDAQ:BBIO) had brought in $12.8 million in revenue and -$1.01 in GAAP EPS, missing analyst estimates for both. H.C. Wainwright reduced the company’s share price target to $22 from $24 in March 2022.
Viking Global had owned 26.6 million BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares as part of its fourth quarter of 2021 investment portfolio. These were worth $444 million. Insider Monkey raked through 924 hedge fund portfolios for Q4 2021 to find out that 25 had also invested in the company.
BridgeBio Pharma, Inc. (NASDAQ:BBIO)’s largest investor after Mr. Halvorsen’s hedge fund is Joseph Edelman’s Perceptive Advisors which owns seven million shares that are worth $118 million.
1. Roivant Sciences Ltd. (NASDAQ:ROIV)
Viking Global’s Stake Value: $889 million
Percentage of Viking Global’s 13F Portfolio: 2.57%
Number of Hedge Fund Holders: 23
Share Price on April 26, 2022: $3.8
Roivant Sciences Ltd. (NASDAQ:ROIV) is a British biotechnology company based in London. The firm develops treatments for cancers, tumors, dermatitis, sickle cell diseases, thyroid eye problems, and more.
Roivant Sciences Ltd. (NASDAQ:ROIV) managed to bring in $24.34 million in revenue and -$0.41 in GAAP EPS for its fourth fiscal quarter. Goldman Sachs set a $15 price target for the company in December 2021, as it explained that the company’s subsidiaries have a promising future.
Mr. Halvorsen’s Viking Global owned a massive $889 million stake in Roivant Sciences Ltd. (NASDAQ:ROIV) as part of its Q4 2021 investments. The stake came through the firm owning 88 million shares. For the same time period, 23 of the 924 hedge funds part of Insider Monkey’s survey had invested in the company.
Disclosure: None. You can also take a look at 10 Best Semiconductor Stocks to Invest in According to Ken Griffin’s Citadel Investment Group and 12 Best Large-cap Biotech Stocks To Buy Now.
